The treatment of venous thromboembolism with low-molecular-weight heparins: A meta-analysis

Thrombosis and Haemostasis

Volumn 107, Issue 4, 2012, Pages 699-716

  Bochenek, Tomasz ^a   Nizankowski, Rafal ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Low molecular weight heparin LMWH; Meta analysis; Systematic review; Venous thromboembolism; Vitamin K antagonist VKA

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; BEMIPARIN; COUMARIN; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN; WARFARIN;

ARTICLE; BLEEDING; CANCER PATIENT; CLINICAL EFFECTIVENESS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INFORMATION PROCESSING; META ANALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MODELS, STATISTICAL; ODDS RATIO; TREATMENT OUTCOME; VENOUS THROMBOSIS; VITAMIN K;

EID: 84859301608     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th11-08-0565     Document Type: Article

References (37)

1. Goldhaber S. Eradication of hospital-acquired venous thromboembolism. Thromb Haemost 2010; 104: 1089-1092.
2. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
3. Zawilska K, Jaeschke R, Tomkowski W, et al. Polskie wytyczne profilaktyki i leczenia zylnej choroby zakrzepowo-zatorowej. Pol Arch Med Wewn 2009; 119 (Suppl 1): 1-69.
4. Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med 2007; 5: 74-80.
5. Nizankowski R, Pruszczyk P, Torbicki A, et al. Zylna choroba zakrzepowo-zatorowa. In: Szczeklik A (ed.) Choroby wewnetrzne. Medycyna Praktyczna 2005; pp. 401-424.
6. Lopez-Beret P, Orgaz A, Fontcuberta J, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg. 2001; 33: 77-90.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
8. Alderson P, Green S. Additional Module 2. In: Cochrane Collaboration open learning material for reviewers. Version1.1.; The Cochrane Collaboration 2002; 6.
9. Higgins J, Thompson SG, Deeks JJ, et al. Measuring incosistency in meta-analyses. Br Med J 2003; 327: 557-560.
10. Moher D, Eastwood S, Olkin I, et al. for the QUORUM Group. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUORUM statement. Lancet 1999; 354: 1896-1900.
11. Beckman JA, Dunn K, Sasahara AA, et al. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thromb Haemost 2003; 89: 953-958.
12. Das SK, Cohen AT, Edmondson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996; 20: 521-527.
13. Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 2005; 29: 638-650.
14. Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12: 389-396.
15. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999; 30: 283-292.
16. Hull RD, Pineo GF, Braut RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-1072.
17. Hull RD, Pineo GF, Braut GF, et al. Self-managed long-term low-molecularweight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120: 72-82.
18. Kakkar VV, Gebska M, Kadziola Z, et al. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost 2003; 89: 674-680.
19. Kucher N, Quiroz R, McKean S, et al. Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vasc Med 2005; 10: 251-256.
20. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
21. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2129.
22. Lopaciuk S, Bielska-Falda H, Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1998; 81: 26-31.
23. Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003; 109: 85-92.
24. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-1735.
25. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-197.
26. Veiga F, Escriba A, Maluenda MP, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000; 84: 559-564.
27. Hamann H. Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis. Zentralbl Chir 1999; 124: 24-26.
28. Hamann H. Rezidivprophylaxe nach Phlebothrombose - orale Antikoagulation oder niedermolekulares Heparin subkutan? Vasomed 1998; 10: 133-136.
29. van der Heijden JF, Hutten BA, Buller HR, et al. Vitamin K antagonists or low-molecular- weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database of Systematic Reviews: Cochrane Collaboration; 2001.
30. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003; 1: 1906-1913.
31. Conti S, Guercini F, Ioro A. Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1.726 patients treated for at least three months. Pathophysiol Haemost Thromb 2003; 33: 197-201.
32. Ferretti G, Bria E, Giannarelli D, et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest 2006; 130: 1808-1816.
33. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006, Chichester, UK: John Wiley & Sons, Ltd; pp. 140-142.
34. Spencer F, Gore J, Reed G, et al., Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study., Thromb Haemost 2009; 101: 878-885.
35. Glynn R. Methodological issues affecting estimates of bleeding risks and consequences after venous thromboembolism, Thromb Haemost 2009; 101: 797-798.
36. Merli GJ, Groce JB. Pharmacological and clinical differences between low-molecular- weight heparins. Implications for prescribing practice and therapeutic interchange. P&T 2010, 35: 95-105.
37. Dolovich LR, Ginsberg JS, Douketis JD, et al. Meta-analysis comparing low-molecular- weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, products type, and dosing frequency. Arch Intern Med 2000, 160: 181-188.